- Home
- CCO vs PCRX Comparison
CCO vs PCRX Comparison
Compare CCO & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCO
- PCRX
- Stock Information
- Founded
- CCO 1995
- PCRX 2006
- Country
- CCO United States
- PCRX United States
- Employees
- CCO N/A
- PCRX N/A
- Industry
- CCO Advertising
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CCO Consumer Discretionary
- PCRX Health Care
- Exchange
- CCO Nasdaq
- PCRX Nasdaq
- Market Cap
- CCO 674.9M
- PCRX 1.1B
- IPO Year
- CCO 2005
- PCRX 2011
- Fundamental
- Price
- CCO $1.11
- PCRX $22.69
- Analyst Decision
- CCO Buy
- PCRX Buy
- Analyst Count
- CCO 3
- PCRX 9
- Target Price
- CCO $2.05
- PCRX $26.22
- AVG Volume (30 Days)
- CCO 1.8M
- PCRX 823.4K
- Earning Date
- CCO 05-08-2025
- PCRX 05-06-2025
- Dividend Yield
- CCO N/A
- PCRX N/A
- EPS Growth
- CCO N/A
- PCRX N/A
- EPS
- CCO N/A
- PCRX N/A
- Revenue
- CCO $1,505,230,000.00
- PCRX $700,966,000.00
- Revenue This Year
- CCO $6.23
- PCRX $9.77
- Revenue Next Year
- CCO $4.07
- PCRX $9.83
- P/E Ratio
- CCO N/A
- PCRX N/A
- Revenue Growth
- CCO 4.95
- PCRX 3.85
- 52 Week Low
- CCO $1.09
- PCRX $11.16
- 52 Week High
- CCO $1.88
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- CCO 28.12
- PCRX 40.27
- Support Level
- CCO $1.20
- PCRX $21.83
- Resistance Level
- CCO $1.32
- PCRX $24.23
- Average True Range (ATR)
- CCO 0.08
- PCRX 1.22
- MACD
- CCO -0.01
- PCRX -0.36
- Stochastic Oscillator
- CCO 4.69
- PCRX 17.70
About CCO Clear Channel Outdoor Holdings Inc.
Clear Channel Outdoor Holdings Inc is one of the world's largest outdoor advertising companies. The company is engaged in providing advertising opportunities through billboards, street furniture displays, transit displays, and other out-of-home advertising displays for its clients. Its reportable segment includes America; Airports; Europe-North and Europe-South. The company generates maximum revenue from the America segment. The America segment serves markets throughout the U.S., with over 90% of its revenue generated from billboard displays.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.